Search

Your search keyword '"immunocytokine"' showing total 240 results

Search Constraints

Start Over You searched for: Descriptor "immunocytokine" Remove constraint Descriptor: "immunocytokine"
240 results on '"immunocytokine"'

Search Results

1. High-Affinity Fully Human Anti-EpCAM Antibody with Biased IL-2 Exhibits Potent Antitumor Activity.

2. Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.

Catalog

Books, media, physical & digital resources

3. Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy

4. Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy.

5. Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

6. A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic

7. High-Affinity Fully Human Anti-EpCAM Antibody with Biased IL-2 Exhibits Potent Antitumor Activity

9. GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies.

10. Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen

11. Cyclophosphamide augments the efficacy of in situ vaccination in a mouse melanoma model.

12. Engineering cytokines for cancer immunotherapy: a systematic review.

13. Cyclophosphamide augments the efficacy of in situ vaccination in a mouse melanoma model

14. Soluble Expression of a Neo2/15-Conjugated Single Chain Fv against PD-L1 in Escherichia coli

15. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.

16. Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy.

17. The present and future of immunocytokines for cancer treatment.

18. Targeting PD-1 + T cells with small-format immunocytokines enhances IL-12 antitumor activity.

19. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy

20. Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation.

21. [68Ga]Ga-DOTA-Siglec-9 Detects Pharmacodynamic Changes of FAPTargeted IL2 Variant Immunotherapy in B16-FAP Melanoma Mice.

22. Enhancing aggregate reduction using anion exchange hybrid filter in an immunocytokine diabody fusion protein purification process.

23. Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation

24. [68Ga]Ga-DOTA-Siglec-9 Detects Pharmacodynamic Changes of FAP-Targeted IL2 Variant Immunotherapy in B16-FAP Melanoma Mice

25. Administration of fusion cytokines induces tumor regression and systemic antitumor immunity

26. NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models

27. Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2+ Murine Neuroblastoma

28. Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2+ Murine Neuroblastoma.

29. Results from the gynecological cohort in a phase 1/2 study (KEYNOTE-B59): endometrial and cervical cancer patients responded to novel immunocytokine GI-101.

30. Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing

31. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine

32. Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression

33. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

34. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.

35. Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity.

36. Cytokine/Antibody Fusion Protein Design and Evaluation.

37. Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation

38. Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation.

39. Mitigating the aggregation challenge in immunocytokine production: Strategies during cell line development and purification optimization.

40. An immunocytokine consisting of a TNFR2 agonist and TNFR2 scFv enhances the expansion of regulatory T cells through TNFR2 clustering.

42. Radiotherapy in Combination With Cytokine Treatment

43. Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of its In vitro Antitumor Activity.

44. Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy.

46. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.

47. Radiotherapy in Combination With Cytokine Treatment.

48. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.

49. GEN-1 immunotherapy for the treatment of ovarian cancer.

50. Utilizing Immunocytokines for Cancer Therapy